VRCA Stock Analysis: Verrica Pharmaceuticals Inc.
Verrica Pharmaceuticals Inc., a dermatology therapeutics company, engages in the development and commercialization of medications for the treatment of dermatologic diseases in the United States. The company offers YCANTH (VP-102) a drug-device combination that contains a GMP-controlled formulation of cantharidin for the treatment of molluscum in adult and pediatric patients, as well as for the treatment of common warts. It also develops VP-315, an oncolytic peptide-based injectable therapy that is in phase II clini
- Latest close
- $4.37
- 20-day change
- -13.81%
- Trend state
- LEAN BEAR
- Classification
- Healthcare · Biotechnology
Market context
Verrica Pharmaceuticals Inc. moved -13.81% over the latest 20-session window. BullRecon currently classifies the broader setup as LEAN BEAR.
Latest report
The latest cached company filing period (FY2025 · $35.6M revenue · -$17.9M net income) is used alongside annual and quarterly history. Values remain tied to their reported period.
Six-dimension read
Future is currently the strongest dimension at 5.4/6, while Profitability is the lowest at 0.5/6. Scores are comparative research signals, not forecasts.